Inhibrx Biosciences (INBX) Projected to Announce Quarterly Earnings on Friday

Inhibrx Biosciences (NASDAQ:INBX) will likely be posting its Q3 2026 results after the market closes on Friday, November 13th. Analysts expect the company to announce earnings of ($2.45) per share and revenue of $1.90 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.28) by ($0.06). On average, analysts expect Inhibrx Biosciences to post ($9.91) EPS for the current fiscal year and ($9.34) EPS for the next fiscal year.

Inhibrx Biosciences Stock Performance

Shares of INBX stock opened at $90.59 on Thursday. The stock’s fifty day moving average is $96.79 and its 200-day moving average is $92.02. The stock has a market capitalization of $1.33 billion, a PE ratio of -10.20 and a beta of 4.03. Inhibrx Biosciences has a 52 week low of $57.30 and a 52 week high of $155.29.

Analysts Set New Price Targets

INBX has been the subject of a number of research analyst reports. Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. HC Wainwright initiated coverage on Inhibrx Biosciences in a research note on Monday, August 24th. They set a “buy” rating and a $245.00 target price on the stock. Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research note on Monday, August 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $197.50.

Insider Buying and Selling at Inhibrx Biosciences

In other Inhibrx Biosciences news, Director Jon Kayyem acquired 5,000 shares of the business’s stock in a transaction on Wednesday, September 23rd. The stock was purchased at an average price of $100.00 per share, with a total value of $500,000.00. Following the acquisition, the director directly owned 434,360 shares of the company’s stock, valued at approximately $43,436,000. This trade represents a 1.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark Lappe bought 10,040 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were acquired at an average price of $84.56 per share, for a total transaction of $848,982.40. Following the transaction, the chief executive officer owned 745,588 shares in the company, valued at approximately $63,046,921.28. This represents a 1.36% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 62,540 shares of company stock valued at $6,347,507 and sold 1,500 shares valued at $168,590. Insiders own 18.26% of the company’s stock.

Inhibrx Biosciences Company Profile

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.